INTRODUCTION: All colorectal cancer (CRC) survivors have an increased risk of developing second primary malignancies (SPMs). The association between diabetes mellitus (DM) and the risk of cancer is well known. However, the role of DM and its therapy in the development of SPMs in CRC patients is not well described. METHODS: In this single-institutional retrospective analysis we identified 1,174 colorectal carcinoma patients, median follow-up 10.1 years, (median age 63 years, 724 men). All patients over 18 years with histologically confirmed CRC who were admitted in the period 1.1. 2003- 31.12.2013 and followed-up till 31.12. 2018 at the Masaryk Memorial Cancer Institute (MMCI) were screened for eligibility. The exclusion criteria were CRC diagnosed at autopsy, lost to follow-up and high risk of development of SPMs due to hereditary cancer syndrome. Tumours are considered multiple primary malignancies if arising in different sites and/or are of a different histology or morphology group. Comparisons of the basic characteristics between the patients with SPM and the patients without SPM were performed as well as comparison of the occurrence of SPMs by the site of diagnosis between the DM and non-DM cohorts and survival analyses. RESULTS: A SPM was diagnosed in 234 (20%) patients, DM in 183 (15%) patients. DM was diagnosed in 22.6% of those with SPM vs. in 13.8% of those without SPM (p=0.001). The most common types of SPMs in DM patients were other CRC, kidney, lung, bladder and nonmelanoma skin cancer, but only carcinoma of the liver and bile duct tracts was significantly more common than in the group without DM. Although breast cancer was the second most common in the group with DM, its incidence was lower than in the group without DM, as well as prostate cancer. A significantly higher incidence of SPMs was found in older CRC patients (≥ 65 years) and in those with lower stage colon cancer and DM. No significant difference in DM treatment between those with and without a SPM was observed including analysis of type of insulin. CONCLUSION: CRC patients with diabetes mellitus, especially those with older age, and early stages of colon cancer, should be screened for second primary malignancies more often than the standard population. Patients without DM have longer survival. According to the occurrence of the most common second malignancies, a clinical examination, blood count, and ultrasound of the abdomen is appropriate, together with standard breast and colorectal cancer screening, and lung cancer screening under certain conditions, and should be recommended in CRC survivors especially in patients with intercurrent DM, however the necessary frequency of screening remains unclear.

Central European Institute of Technology Molecular Oncology 2 Solid Cancer Masaryk University Brno Czechia

Clinical Trial Unit Masaryk Memorial Cancer Institute Brno Czechia

Department of Comprehensive Cancer Care Faculty of Medicine Masaryk University Brno Czechia

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czechia

Department of Medical Ethics Faculty of Medicine Masaryk University Brno Czechia

Department of Pharmacology Faculty of Medicine Masaryk University Brno Czechia

Department of Pharmacy Masaryk Memorial Cancer Institute Brno Czechia

Department of Radiation Oncology Faculty of Medicine Masaryk University Brno Czechia

Department of Radiation Oncology Masaryk Memorial Cancer Institute Brno Czechia

Faculty of Medicine Masaryk University Brno Czechia

Institute of Health Information and Statistics of the Czech Republic Prague Czechia

Zobrazit více v PubMed

Dusek L, Pavlík T, Májek O, Büchler T, Muzik J, Maluskova D, et al. Estimating Cancer Incidence, Prevalence, and the Number of Cancer Patients Treated With Antitumor Therapy in 2015 and 2020 - Analysis of the Czech National Cancer Registry. Klin Onkol (2015) 28(1):30–43.  10.14735/amko201530 PubMed DOI

Donin N, Filson C, Drakaki A, Tan HJ, Castillo A, Kwan L, et al. Risk of Second Primary Malignancies Among Cancer Survivors in the United States, 1992 Through 2008. Cancer (2016) 122(19):3075–86.  10.1002/cncr.30164 PubMed DOI PMC

Raj KP, Taylor TH, Wray C, Stamos MJ, Zell JA. Risk of Second Primary Colorectal Cancer Among Colorectal Cancer Cases: A Population-Based Analysis. J Carcinog (2011) 10:6.  10.4103/1477-3163.78114 PubMed DOI PMC

Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and Cancer. Endocr Relat Cancer (2009) 16(4):1103–23.  10.1677/ERC-09-0087 PubMed DOI

Vigneri R, Goldfine ID, Frittitta L. Insulin, Insulin Receptors, and Cancer. J Endocrinol Invest (2016) 39(12):1365–76.  10.1007/s40618-016-0508-7 PubMed DOI

Home P. Insulin Therapy and Cancer. Diabetes Care (2013) 36 Suppl 2(Suppl 2):S240–4.  10.2337/dcS13-2002 PubMed DOI PMC

Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiol Rev (2015) 95(3):727–48.  10.1152/physrev.00030.2014 PubMed DOI PMC

Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and Sulfonylureas in Relation to Cancer Risk in Type II Diabetes Patients: A Meta-Analysis Using Primary Data of Published Studies. Metabolism (2013) 62(7):922–34.  10.1016/j.metabol.2013.01.014 PubMed DOI

Colmers IN, Bowker SL, Tjosvold LA, Johnson JA. Insulin Use and Cancer Risk in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Observational Studies. Diabetes Metab (2012) 38(6):485–506.  10.1016/j.diabet.2012.08.011 PubMed DOI

Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs. Endocr Rev (2001) 22(5):706–17.  10.1210/edrv.22.5.0442 PubMed DOI

Bordeleau L, Yakubovich N, Dagenais GR, Rosenstock J, Probstfield J, Chang Yu P, et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care (2014) 37(5):1360–6.  10.2337/dc13-1468 PubMed DOI

Rosenstock J, Fonseca V, McGill JB, Riddle M, Hallé JP, Hramiak I, et al. Similar Risk of Malignancy With Insulin Glargine and Neutral Protamine Hagedorn (NPH) Insulin in Patients With Type 2 Diabetes: Findings From a 5 Year Randomised, Open-Label Study. Diabetologia (2009) 52(9):1971–3.  10.1007/s00125-009-1452-2 PubMed DOI PMC

Fagot JP, Blotière PO, Ricordeau P, Weill A, Alla F, Allemand H. Does Insulin Glargine Increase the Risk of Cancer Compared With Other Basal Insulins?: A French Nationwide Cohort Study Based on National Administrative Databases. Diabetes Care (2013) 36(2):294–301.  10.2337/dc12-0506 PubMed DOI PMC

Peeters PJ, Bazelier MT, Leufkens HG, Auvinen A, van Staa TP, de Vries F, et al. Insulin Glargine Use and Breast Cancer Risk: Associations With Cumulative Exposure. Acta Oncol (2016) 55(7):851–8.  10.3109/0284186X.2016.1155736 PubMed DOI PMC

Ghosal S, Stephens J, Van Deventer A, Mital V, Jayasinghe P, Khan M, et al. Critical Appraisal of the Recent Data Published on the Link Between Insulin and Cancer. Diabetes Metab Syndr (2011) 5(4):211–3.  10.1016/j.dsx.2012.03.004 PubMed DOI

Home PD, Lagarenne P. Combined Randomised Controlled Trial Experience of Malignancies in Studies Using Insulin Glargine. Diabetologia (2009) 52(12):2499–506.  10.1007/s00125-009-1530-5 PubMed DOI PMC

Wu JW, Filion KB, Azoulay L, Doll MK, Suissa S. Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies. Diabetes Care (2016) 39(3):486–94.  10.2337/dc15-1816 PubMed DOI

Rendell M, Akturk HK, Tella SH. Glargine Safety, Diabetes and Cancer. Expert Opin Drug Saf (2013) 12(2):247–63.  10.1517/14740338.2013.770469 PubMed DOI

Sciacca L, Vella V, Frittitta L, Tumminia A, Manzella L, Squatrito S, et al. Long-acting Insulin Analogs and Cancer. Nutr Metab Cardiovasc Dis (2018) 28(5):436–43.  10.1016/j.numecd.2018.02.010 PubMed DOI

Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and Molecular Mechanisms of Metformin: An Overview. Clin Sci (Lond) (2012) 122(6):253–70.  10.1042/CS20110386 PubMed DOI PMC

Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: A Therapeutic Opportunity in Breast Cancer. Clin Cancer Res (2010) 16(6):1695–700.  10.1158/1078-0432.CCR-09-1805 PubMed DOI PMC

Higurashi T, Hosono K, Takahashi H, Komiya Y, Umezawa S, Sakai E, et al. Metformin for Chemoprevention of Metachronous Colorectal Adenoma or Polyps in Post-Polypectomy Patients Without Diabetes: A Multicentre Double-Blind, Placebo-Controlled, Randomised Phase 3 Trial. Lancet Oncol (2016) 17(4):475–83.  10.1016/S1470-2045(15)00565-3 PubMed DOI

Kim YH, Noh R, Cho SY, Park SJ, Jeon SM, Shin HD, et al. Inhibitory Effect of Metformin Therapy on the Incidence of Colorectal Advanced Adenomas in Patients With Diabetes. Intest Res (2015) 13(2):145–52.  10.5217/ir.2015.13.2.145 PubMed DOI PMC

Najafi M, Cheki M, Rezapoor S, Geraily G, Motevaseli E, Carnovale C, et al. Metformin: Prevention of Genomic Instability and Cancer: A Review. Mutat Res Genet Toxicol Environ Mutagen (2018) 827:1–8.  10.1016/j.mrgentox.2018.01.007 PubMed DOI

Alcusky M, Keith SW, Karagiannis T, Rabinowitz C, Louis DZ, Maio V. Metformin Exposure and Survival in Head and Neck Cancer: A Large Population-Based Cohort Study. J Clin Pharm Ther (2019) 44(4):588–94.  10.1111/jcpt.12820 PubMed DOI

Tseng CH. Metformin and Lung Cancer Risk in Patients With Type 2 Diabetes Mellitus. Oncotarget (2017) 8(25):41132–42.  10.18632/oncotarget.17066 PubMed DOI PMC

Tseng CH. Use of Metformin and Risk of Kidney Cancer in Patients With Type 2 Diabetes. Eur J Cancer (2016) 52:19–25.  10.1016/j.ejca.2015.09.027 PubMed DOI

Liu F, Yan L, Wang Z, Lu Y, Chu Y, Li X, et al. Metformin Therapy and Risk of Colorectal Adenomas and Colorectal Cancer in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis. Oncotarget (2017) 8(9):16017–26.  10.18632/oncotarget.13762 PubMed DOI PMC

Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an Adjuvant Treatment for Cancer: A Systematic Review and Meta-Analysis. Ann Oncol (2016) 27(12):2184–95.  10.1093/annonc/mdw410 PubMed DOI PMC

Ding L, Liang G, Yao Z, Zhang J, Liu R, Chen H, et al. Metformin Prevents Cancer Metastasis by Inhibiting M2-like Polarization of Tumor Associated Macrophages. Oncotarget (2015) 6(34):36441–55.  10.18632/oncotarget.5541 PubMed DOI PMC

Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis. Cancer Prev Res (Phila) (2010) 3(11):1451–61.  10.1158/1940-6207.CAPR-10-0157 PubMed DOI

Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, et al. Multiple Primary Tumours: Challenges and Approaches, a Review. ESMO Open (2017) 2(2):e000172.  10.1136/esmoopen-2017-000172. eCollection 2017. PubMed DOI PMC

SEER Training Modules Multiple primary neoplasms. U. S. National Institutes of Health: National Cancer Institute; Available at: https://training.seer.cancer.gov/. [Retrieved June 10, 2020]

Working Group Report International Rules for Multiple Primary Cancers (ICD-0 Third Edition). Eur J Cancer Prev (2005) 14(4):307–8.  10.1097/00008469-200508000-00002 PubMed DOI

Institute of Health Information and Statistics of the Czech Republic National Health Information System (NHIS), Czech National Cancer Registry (CNCR). http://www.uzis.cz/en/czech-nationalcancer-registry-cncr. [Retrieved June 10, 2020]

Jia H, Li Q, Yuan J, Sun X, Wu Z. Second Primary Malignancies in Patients With Colorectal Cancer: A Population-Based Analysis. Oncologist (2020) 25 (4):e644–50.  10.1634/theoncologist.2019-0266 PubMed DOI PMC

La Francis IE, Cooper RB. Second Primary Malignancies Associated With Primary Female Breast Cancer: A Review of the Danbury Hospital Experience. Conn Med (1992) 56(8):411–4. PubMed

Duchateau CS, Stokkel MP. Second Primary Tumors Involving Non-Small Cell Lung Cancer: Prevalence and Its Influence on Survival. Chest (2005) 127 (4):1152–8.  10.1378/chest.127.4.1152 PubMed DOI

Lee YT, Liu CJ, Hu YW, Teng CJ, Tzeng CH, Yeh CM, et al. Incidence of Second Primary Malignancies Following Colorectal Cancer: A Distinct Pattern of Occurrence Between Colon and Rectal Cancers and Association of Co-Morbidity With Second Primary Malignancies in a Population-Based Cohort of 98,876 Patients in Taiwan. Medicine (Baltimore) (2015) 94(26):e1079.  10.1097/MD.0000000000001079 PubMed DOI PMC

Takeuchi D, Koide N, Komatsu D, Okumura M, Suzuki A, Miyagawa S. Relationships of Obesity and Diabetes Mellitus to Other Primary Cancers in Surgically Treated Gastric Cancer Patients. Int J Surg (2014) 12(6):587–93.  10.1016/j.ijsu.2014.04.012 PubMed DOI

Broman KK, Bailey CE, Parikh AA. Sidedness of Colorectal Cancer Impacts Risk of Second Primary Gastrointestinal Malignancy. Ann Surg Oncol (2019) 26(7):2037–43.  10.1245/s10434-019-07326-7 PubMed DOI

Li CI, Daling JR, Tang MT, Malone KE. Relationship between diabetes and risk of second primary contralateral breast cancer. Breast Cancer Res Treat (2011) 125(2):545–51.  10.1007/s10549-010-1035-4 PubMed DOI PMC

Zhuang L, Yan X, Meng Z. Second primary malignancy in patients with cholangiocarcinoma: a population-based study. Cancer Manag Res (2019) 11:1969–83.  10.2147/CMAR.S187614 PubMed DOI PMC

González N, Prieto I, Del Puerto-Nevado L, Portal-Nuñez S, Ardura JA, Corton M, et al. 2017 Update on the Relationship Between Diabetes and Colorectal Cancer: Epidemiology, Potential Molecular Mechanisms and Therapeutic Implications. Oncotarget (2017) 8(11):18456–85.  10.18632/oncotarget.14472 PubMed DOI PMC

Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, Korc M. Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer: A Retrospective Cohort Study of Older Medicare Patients. Diabetes Care (2011) 34(9):1965–71.  10.2337/dc11-0699 PubMed DOI PMC

Kwon M, Roh JL, Song J, Lee SW, Kim SB, Choi SH, et al. Effect of Metformin on Progression of Head and Neck Cancers, Occurrence of Second Primary Cancers, and Cause-Specific Survival. Oncologist (2015) 20(5):546–53.  10.1634/theoncologist.2014-0426 PubMed DOI PMC

Zhou PT, Li B, Liu FR, Zhang MC, Wang Q, Li YY, et al. Metformin Is Associated With Survival Benefit in Pancreatic Cancer Patients With Diabetes: A Systematic Review and Meta-Analysis. Oncotarget (2017) 8(15):25242–50.  10.18632/oncotarget.15692 PubMed DOI PMC

Bradley MC, Ferrara A, Achacoso N, Ehrlich SF, Quesenberry CP, Jr, Habel LA. A Cohort Study of Metformin and Colorectal Cancer Risk Among Patients With Diabetes Mellitus. Cancer Epidemiol Biomarkers Prev (2018) 27(5):525–30.  10.1158/1055-9965.EPI-17-0424 PubMed DOI PMC

Dankner R, Balicer R, Boffetta P, Boker LK, Wallenstein S, Freedman L, et al. Diabetes, Glucose Control, Glucose Lowering Medications, and Cancer Risk: A 10-year Population-Based Historical Cohort. BMC Cancer (2012) 12:364.  10.1186/1471-2407-12-364 PubMed DOI PMC

Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, et al. Risk of cancer in patients on insulin glargine and other insulin analogs in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia (2012) 55:51–62.  10.1007/s00125-011-2312-4 PubMed DOI PMC

Karlstad O, Starup-Linde J, Vestergaard P, Hjellvik V, Bazelier MT, Schmidt MK, et al. Use of Insulin and Insulin Analogs and Risk of Cancer - Systematic Review and Meta-Analysis of Observational Studies. Curr Drug Saf (2013) 8(5):333–48.  10.2174/15680266113136660067 PubMed DOI PMC

Mayer D, Chantelau E. Treatment With Insulin Glargine (Lantus) Increases the Proliferative Potency of the Serum of Patients With type-1 Diabetes: A Pilot Study on MCF-7 Breast Cancer Cells. Arch Physiol Biochem (2010) 116(2):73–8.  10.3109/13813451003631439 PubMed DOI

But A, De Bruin ML, Bazelier MT, Hjellvik V, Andersen M, Auvinen A, et al. Cancer Risk Among Insulin Users: Comparing Analogues With Human Insulin in the CARING Five-Country Cohort Study. Diabetologia (2017) 60(9):1691–703.  10.1007/s00125-017-4312-5 PubMed DOI PMC

Gibson TM, Park Y, Robien K, Shiels MS, Black A, Sampson JN, et al. Body Mass Index and Risk of Second Obesity-Associated Cancers After Colorectal Cancer: A Pooled Analysis of Prospective Cohort Studies. J Clin Oncol (2014) 32(35):4004–11.  10.1200/JCO.2014.56.8444 PubMed DOI PMC

Morais S, Castro C, Antunes L, Peleteiro B, Bento MJ, Lunet N. Second Primary Cancers and Survival in Patients With Gastric Cancer: Association With Prediagnosis Lifestyles. Eur J Cancer Prev (2019) 28(3):159–66.  10.1097/CEJ.0000000000000447 PubMed DOI

Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction. J Clin Oncol (2012) 30(30):3734–45.  10.1200/JCO.2012.41.8681 PubMed DOI

Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients